{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:19:20Z","timestamp":1782940760436,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:00:00Z","timestamp":1572220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:00:00Z","timestamp":1572220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Direct Acting Antiviral (DAAs) drugs have a much lower burden of treatment and monitoring requirements than regimens containing interferon and ribavirin, and a much higher efficacy in treating hepatitis C (HCV). These characteristics mean that initiating treatment and obtaining a virological cure (Sustained Viral response, SVR) on completion of treatment, in non-specialist environments should be feasible. We investigated the English-language literature evaluating community and primary care-based pathways using DAAs to treat HCV infection.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Databases (Cinahl; Embase; Medline; PsycINFO; PubMed) were searched for studies of treatment with DAAs in non-specialist settings to achieve SVR. Relevant studies were identified including those containing a comparison between a community and specialist services where available. A narrative synthesis and linked meta-analysis were performed on suitable studies with a strength of evidence assessment (GRADE).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventeen studies fulfilled the inclusion criteria: five from Australia; two from Canada; two from UK and eight from USA. Seven studies demonstrated use of DAAs in primary care environments; four studies evaluated integrated systems linking specialists with primary care providers; three studies evaluated services in locations providing care to people who inject drugs; two studies evaluated delivery in pharmacies; and one evaluated delivery through telemedicine. Sixteen studies recorded treatment uptake. Patient numbers varied from around 60 participants with pathway studies to several thousand in two large database studies. Most studies recruited less than 500 patients. Five studies reported reduced SVR rates from an intention-to-treat analysis perspective because of loss to follow-up before the final confirmatory SVR test. GRADE assessments were made for uptake of HCV treatment (medium); completion of HCV treatment (low) and achievement of SVR at 12\u2009weeks (medium).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Services sited in community settings are feasible and can deliver increased uptake of treatment. Such clinics are able to demonstrate similar SVR rates to published studies and real-world clinics in secondary care. Stronger study designs are needed to confirm the precision of effect size seen in current studies. Prospero: CRD42017069873.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-019-4635-7","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T17:05:08Z","timestamp":1572282308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4772-2388","authenticated-orcid":false,"given":"Andrew","family":"Radley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther J.","family":"Aspinall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Angus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lex","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,28]]},"reference":[{"key":"4635_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"The Polaris HCV Collaborators","year":"2017","unstructured":"The Polaris HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161\u201376. \n                    https:\/\/doi.org\/10.1016\/S2468-1253(16)30181-9\n                    \n                  .","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4635_CR2","unstructured":"WHO. Global hepatitis report 2017. World Health Organization; Geneva 2017. \n                    https:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/"},{"key":"4635_CR3","unstructured":"WHO 2016. Combating hepatitis B and C to reach elimination by 2030 \u2013 advocacy brief. World Health Organization, Geneva May 2016. \n                    http:\/\/www.who.int\/hepatitis\/publications\/hep-elimination-by-2030-brief\/en\/"},{"key":"4635_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugpo.2017.07.002","volume":"47","author":"S Bajis","year":"2017","unstructured":"Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, Grebely J. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review. Int J Drug Policy. 2017;47:34\u201346. \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2017.07.002\n                    \n                  .","journal-title":"Int J Drug Policy"},{"key":"4635_CR5","unstructured":"World Health Organization Global Health Sector Strategy on Viral Hepatitis 2016-2021. Towards ending viral hepatitis. World Health Organization Geneva 2016 \n                    https:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/"},{"key":"4635_CR6","doi-asserted-by":"publisher","unstructured":"Harris M, Rhodes. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors Harm Reduction Journal 2013 10, 7. doi: \n                    https:\/\/doi.org\/10.1186\/1477-7517-10-7\n                    \n                  .","DOI":"10.1186\/1477-7517-10-7"},{"key":"4635_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.drugpo.2013.11.004","volume":"25","author":"L Jones","year":"2014","unstructured":"Jones L, Atkinson A, Bates G, McCoy E, Porcellato L, Beynon C. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: systematic review of qualitative research. Int J Drug Policy. 2014;25:204\u201311 \n                    10.10.1016\/j.drugpo.2013.11.004\n                    \n                  .","journal-title":"Int J Drug Policy"},{"key":"4635_CR8","doi-asserted-by":"publisher","unstructured":"Dowsett LE, Coward S, Lorenzetti DL, MacKean G, Clement F. Living with hepatitis C virus: a systematic review and narrative synthesis of qualitative literature. Can J Gastroenterol Hepatol. 2017. \n                    https:\/\/doi.org\/10.1155\/2017\/3268650\n                    \n                  .","DOI":"10.1155\/2017\/3268650"},{"key":"4635_CR9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/jvh.12844","volume":"25","author":"R Simmons","year":"2018","unstructured":"Simmons R, Ireland G, Irving W, Hickman M, Sabin C, Ijaz S, Ramsay M, Lattimore S, Mandal S. Establishing the cascade of care for hepatitis C in England\u2014benchmarking to monitor impact of direct acting antivirals. J Viral Hepat. 2018;25:482\u201390. \n                    https:\/\/doi.org\/10.1111\/jvh.12844\n                    \n                  .","journal-title":"J Viral Hepat"},{"key":"4635_CR10","volume-title":"Hepatitis C among drug users in Europe: epidemiology, treatment and prevention, EMCDDA insights 23","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2016","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Hepatitis C among drug users in Europe: epidemiology, treatment and prevention, EMCDDA insights 23. Luxembourg: Publications Office of the EU; 2016."},{"key":"4635_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.drugpo.2017.08.001","volume":"47","author":"J Grebely","year":"2017","unstructured":"Grebely J, Bruneau J, Bruggmann P, Harris M, Hickman M, Rhodes T, Treloar C. Elimination of hepatitis C virus infection among PWID: the beginning of a new era of interferon-free DAA therapy. Int J Drug Policy. 2017;47:26\u201333. \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2017.08.001\n                    \n                  .","journal-title":"Int J Drug Policy"},{"key":"4635_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12879-016-1548-5","volume":"16","author":"AJ Wade","year":"2016","unstructured":"Wade AJ, Veronese V, Hellard ME, Doyle JS. A systematic review of community based hepatitis C treatment. BMC Infect Dis. 2016;16:202. \n                    https:\/\/doi.org\/10.1186\/s12879-016-1548-5\n                    \n                  .","journal-title":"BMC Infect Dis"},{"key":"4635_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JD, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166:637\u201348. \n                    https:\/\/doi.org\/10.7326\/M16-2575\n                    \n                  .","journal-title":"Ann Intern Med"},{"key":"4635_CR14","unstructured":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018. \n                    https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/273174\/9789241550345-eng.pdf?ua=1"},{"key":"4635_CR15","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, Clarke M, Devereaux J, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J. 2009;339:b2700. \n                    https:\/\/doi.org\/10.1136\/bmj.b2700\n                    \n                  .","journal-title":"Br Med J"},{"issue":"11","key":"4635_CR16","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S2468-1253(17)30053-5","volume":"2","author":"B Emmanuel","year":"2017","unstructured":"Emmanuel B, Wilson EM, O'Brien TR, Kottilil S, Lau G. Shortening the duration of therapy for chronic hepatitis C infection. Lancet Gastroenterol Hepatol. 2017;2(11):832\u20136. \n                    https:\/\/doi.org\/10.1016\/S2468-1253(17)30053-5\n                    \n                  .","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4635_CR17","unstructured":"World Health Organisation. Main terminology \u2013 primary health care. \n                    http:\/\/www.euro.who.int\/en\/health-topics\/Health-systems\/primary-health-care\/main-terminology\n                    \n                   ()."},{"key":"4635_CR18","unstructured":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from \n                    http:\/\/handbook.cochrane.org\n                    \n                  . ()."},{"key":"4635_CR19","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses \n                    http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp\n                    \n                   ()."},{"key":"4635_CR20","doi-asserted-by":"publisher","unstructured":"Sabbagh HJ, Hassan M, Hassan A, Innes NP, Elkday HM, Little J, Massey PA. Passive smoking in the etiology of non-Syndromic Orofacial clefts: a systematic review and meta-analysis. PLoS One. 2015. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0116963\n                    \n                  .","DOI":"10.1371\/journal.pone.0116963"},{"key":"4635_CR21","doi-asserted-by":"publisher","first-page":"1312e1324","DOI":"10.1016\/j.jclinepi.2014.11.023","volume":"68","author":"ND Berkman","year":"2015","unstructured":"Berkman ND, Lohr KN, Ansari MT, Balk EM, Kane R, McDonagh M, Morton SC, Viswanathan M, Bass EB, Butler M, Gartlehener G, Hartley L, McPheteers M, Morgan LC, Reston J, Sista P, Whitlock E, Chang S. Grading the strength of a body of evidence when assessing health care interventions: an EPC update. J Clin Epidemiol. 2015;68:1312e1324.","journal-title":"J Clin Epidemiol"},{"key":"4635_CR22","doi-asserted-by":"publisher","unstructured":"Bloom S, Lubel J, Nicoll A, Gow P, Dev A, Roberts S, Bell S, Kronberg I, Knight V, Sood S, Lewis D, Kemp W, On behalf of the Melbourne Liver Group. Comparison of direct-acting antiviral therapy for hepatitis C between specialist centres and primary care: efficacy and adherence to response assessment. J Gastroenterol Hepatol. 2017;32, 65(suppl 2). \n                    https:\/\/doi.org\/10.1111\/jgh.13892\n                    \n                  .","DOI":"10.1111\/jgh.13892"},{"issue":"5","key":"4635_CR23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.5604\/01.3001.0010.2757","volume":"16","author":"JW Francheville","year":"2017","unstructured":"Francheville JW, Rankin R, Beck J, Hoare C, Materniak S, German G, Barrett L, Bunimov-Wall N, Smyth D. Early success in an open access provincially funded hepatitis C treatment program in Prince Edward Island. Ann Hepatol. 2017;16(5):749\u201358. \n                    https:\/\/doi.org\/10.5604\/01.3001.0010.2757\n                    \n                  .","journal-title":"Ann Hepatol"},{"key":"4635_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.7326\/M17-0118","volume":"167","author":"S Kattakuzhy","year":"2017","unstructured":"Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, Akoth E, Thomas A, Ahmed C, Espinosa M, Price A, Rosenthal E, Tang L, Wilson E, Bentzen S, Masur H, Kottilil S, the ASCEND Providers. Expansion of treatment for hepatitis C virus infection by task shifting to community-based non-specialist providers: a nonrandomized clinical trial. Ann Inter Med. 2017;167:311\u20138. \n                    https:\/\/doi.org\/10.7326\/M17-0118\n                    \n                  .","journal-title":"Ann Inter Med"},{"key":"4635_CR25","doi-asserted-by":"publisher","unstructured":"McClure T, Olenski M, Ward A, Glasgow S, Stothers L, New K, Papaluca T, Wong D, Burns G, Valaydon Z, Mei SCY, Jeremiah C, Visvanathan K, Croagh C, Howell J, Hong T, Ryan M, Demeduik B, Lust M, Shaw G, Iser D, Nguyen T, Desmond P, Bell S , Thompson AJ. Real-world treatment for hepatitis C in the direct acting antiviral era: Comparing outcomes between the tertiary liver clinic and community J Gastroenterol Hepatol 2017; 32: (suppl 2): 74. DOI:\n                    https:\/\/doi.org\/10.1111\/jgh.13892","DOI":"10.1111\/jgh.13892"},{"key":"4635_CR26","unstructured":"Miller L, Quairoli K, Lom J, Fluker SA. Access to and success with new hepatitis c therapy in an urban primary care centre. J. General Internal Medicine 2016: 31 (2) 1: S110. \n                    10.1007%2Fs11606-016-3657-7"},{"key":"4635_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.drugpo.2017.07.021","volume":"47","author":"BL Norton","year":"2017","unstructured":"Norton BL, Fleming J, Bachhuber MA, Steinman M, DeLuca J, Cunningham CO, Johnson N, Laraque F, Litwin AH. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy. 2017;47:196\u2013201 \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2017.07.021\n                    \n                  .","journal-title":"Int J Drug Policy"},{"key":"4635_CR28","doi-asserted-by":"publisher","unstructured":"Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME. Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs. Clin Infect Dis. 2019:ciz546. \n                    https:\/\/doi.org\/10.1093\/cid\/ciz546\n                    \n                  .","DOI":"10.1093\/cid\/ciz546"},{"key":"4635_CR29","unstructured":"Abdulameer A, Leff P, Joshi K, Hepner A, Moore A, Arendt K, Reynolds J, Gish R, Manch R, Kohli A. Effectiveness of sofosbuvir\/ledipasvir and sofosbuvir\/ simeprevir for the treatment of hepatitis C genotype-1: Real world analysis. Hepatology 2016; 64 (1) S1: 989A-990A."},{"issue":"4","key":"4635_CR30","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ammed.2016.11.019","volume":"130","author":"LA Beste","year":"2017","unstructured":"Beste LA, Glorioso TJ, Ho PM, Au DH, Kirsch SR, Todd-Stenberg J, Chang MF, Dominitz JA, Baron AE. Telemedicine speciality support promoites hepatitis C treatment by primary care providers in the department of vetrerans affairs. Am J Med. 2017;130(4):432\u20138. \n                    https:\/\/doi.org\/10.1016\/j.ammed.2016.11.019\n                    \n                  .","journal-title":"Am J Med"},{"issue":"suppl1","key":"4635_CR31","first-page":"A1","volume":"64","author":"R Buchanan","year":"2015","unstructured":"Buchanan R, Shalabi A, Parkes J, Khakoo S. Hepatology outreach services to overcome inequalities in hepatitis C care in an isolated UK population (PTU 112). Gut. 2015;64(suppl1):A1\u2013A584.","journal-title":"Gut"},{"key":"4635_CR32","doi-asserted-by":"publisher","first-page":"S631","DOI":"10.1016\/S0168-8278(16)01600-7","volume":"64","author":"F Georgie","year":"2016","unstructured":"Georgie F, Nafisi S, Kohli A, Thornton K, Reynolds J, Moore A, Gish R, Scott J, Deming P, Sedillo M, Qualls C, Box T, Cox P, Mera J, Miller A, Sussman N, Khaderi S, Manch R, Arora S. Primary care physicians utilising the ECHO model equally effective as subspecialists treating HCV using direct-acting antivirals-only regimens: results of the ECHO model (SAT-260). J Hepatol. 2016;64:S631\u2013832. \n                    https:\/\/doi.org\/10.1016\/S0168-8278(16)01600-7\n                    \n                  .","journal-title":"J Hepatol"},{"key":"4635_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.sat.2016.12.014","volume":"75","author":"JL Butner","year":"2017","unstructured":"Butner JL, Gupta N, Fabian C, Henry S, Shi JM, Tetrault JM. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. J Subst Abus Treat. 2017;75:49\u201353. \n                    https:\/\/doi.org\/10.1016\/j.sat.2016.12.014\n                    \n                  .","journal-title":"J Subst Abus Treat"},{"key":"4635_CR34","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.drugpo.2017.05.056","volume":"47","author":"L Morris","year":"2017","unstructured":"Morris L, Smirnov A, Kvassay A, Leslie E, Kavanagh R, Alexander N, Davey G, Williams O, Gilks C, Najman J. Initial outcomes of integrated community-based hepatitis c treatment for people who inject drugs: findings from the Queensland injectors\u2019 health network. Int J Drug Policy. 2017;47:216\u201320. \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2017.05.056\n                    \n                  .","journal-title":"Int J Drug Policy"},{"key":"4635_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.drugpo.2017.05.032","volume":"47","author":"P Read","year":"2017","unstructured":"Read P, Lothian R, Chronister K, Gilliver R, Kearley J, Dore GJ, van Beck I. Delivering direct acting antiviral therapy for hepatitis c to highly marginalised and current drug injecting populations in atargeted primary health care setting. Int J Drug Policy. 2017;47:209\u201315. \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2017.05.032\n                    \n                  .","journal-title":"Int J Drug Policy"},{"key":"4635_CR36","unstructured":"David C, David D, Essex W, Deming P, Qualls CR, Mera J. Hepatitis c treatment outcomes in a pharmacist-managed clinic in a rural tribal health system. Hepatology 2017; 66 (s1): 331A. Poster 609."},{"key":"4635_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.drugpo.2017.05.042","volume":"47","author":"A Radley","year":"2017","unstructured":"Radley A, Tait J, Dillon JF. DOT-C: a cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitution therapy from a community pharmacy. Int J Drug Policy. 2017;47:126\u201336. \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2017.05.042\n                    \n                  .","journal-title":"Int J Drug Policy"},{"issue":"6","key":"4635_CR38","doi-asserted-by":"publisher","first-page":"874","DOI":"10.5604\/01.3001.0010.5277","volume":"16","author":"CL Cooper","year":"2017","unstructured":"Cooper CL, Hatashita H, Corsi DJ, Parmar P, Corrin R, Garber G. Direct-acting antiviral therapy outcomes in Canadian chronic hepatitis c telemedicine patients. Ann Hepatol. 2017;16(6):874\u201380. \n                    https:\/\/doi.org\/10.5604\/01.3001.0010.5277\n                    \n                  .","journal-title":"Ann Hepatol"},{"key":"4635_CR39","doi-asserted-by":"publisher","unstructured":"N\u00ed Cheallaigh C, O\u2019Leary A, Keating S, Singleton A, Heffernan S, Keenan E, Robson L, Sears J, Moloney J, Arora S, Bergin C, Norris S On behalf of the Irish Hepatitis C Outcomes Research Network. Telementoring with project ECHO: a pilot study in Europe. BMJ Innovations 2017;3:144\u2013151. doi:\n                    https:\/\/doi.org\/10.1136\/bmjinnov-2016-000141\n                    \n                  .","DOI":"10.1136\/bmjinnov-2016-000141"},{"key":"4635_CR40","doi-asserted-by":"crossref","unstructured":"Shehata N, Austin T, Ha S, Timmerman K. Barriers and facilitators of hepatitis C virus screening and testing: a scoping review Canadian Communicable Diseases Reports 2018; 44:7\u20138. PMID:31011297","DOI":"10.14745\/ccdr.v44i78a03"},{"key":"4635_CR41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10654-014-9958-4","volume":"30","author":"EJ Aspinall","year":"2015","unstructured":"Aspinall EJ, Doyle JS, Corson S, Hellard ME, Hunt D, Goldberg D, Nguyen T, Ytter YF, Morgan RL, Smith B, Stoove M, Wiktor SZ, Hutchinson S. Targeted hepatitis C antibody testing interventions: a systematic review. Eur J Epidemiol. 2015;30:115\u201329. \n                    https:\/\/doi.org\/10.1007\/s10654-014-9958-4\n                    \n                  .","journal-title":"Eur J Epidemiol"},{"key":"4635_CR42","doi-asserted-by":"crossref","unstructured":"McDermott CL; Lockhart CM, Devine B. Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis. J Virus Eradication 2018; 4 (2): 118\u2013122. PMC5892673.","DOI":"10.1016\/S2055-6640(20)30255-7"},{"issue":"1","key":"4635_CR43","doi-asserted-by":"publisher","first-page":"22146","DOI":"10.7448\/IAS.20.1.22146","volume":"20","author":"J Grebely","year":"2017","unstructured":"Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030 - what will it take to get there? J Int AIDS Soc. 2017;20(1):22146. \n                    https:\/\/doi.org\/10.7448\/IAS.20.1.22146\n                    \n                  .","journal-title":"J Int AIDS Soc"},{"key":"4635_CR44","doi-asserted-by":"publisher","unstructured":"Wade AJ, McCormack A, Roder C, McDonald K, Davies M, Scott N, Wardrop M, AThan E, Hellard ME. Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct-acting antiviral therapy for hepatitis C. J Viral Hepat. 2018:1\u201310. \n                    https:\/\/doi.org\/10.1111\/jvh.12910\n                    \n                  .","DOI":"10.1111\/jvh.12910"},{"key":"4635_CR45","doi-asserted-by":"publisher","unstructured":"A de Bruin M, Inglis SK, Donnan PT, Dillon JF. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for Hepatitis C in patients receiving opioid substitution therapy: A study protocol for \u201cSuperDOT-C\u201d \u2013a pragmatic cluster randomised trial. BMJ Open 2018 DOI: \n                    https:\/\/doi.org\/10.1136\/bmjopen-2017-021443","DOI":"10.1136\/bmjopen-2017-021443"},{"key":"4635_CR46","doi-asserted-by":"publisher","unstructured":"Swan D, Cullen W, Macias J, Oprea C, Story A, Surey J, Vickerman P S. Lambert JS. Hepcare Europe - bridging the gap in the treatment of hepatitis C: study protocol, Expert Review of Gastroenterology & Hepatology 2018, 12:3, 303\u2013314, DOI: \n                    https:\/\/doi.org\/10.1080\/17474124.2018.1424541","DOI":"10.1080\/17474124.2018.1424541"},{"key":"4635_CR47","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/hep.26431","volume":"58","author":"NK Martin","year":"2013","unstructured":"Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58:1598\u2013609. \n                    https:\/\/doi.org\/10.1002\/hep.26431\n                    \n                  .","journal-title":"Hepatology"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-019-4635-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-019-4635-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-019-4635-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:29:29Z","timestamp":1603758569000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-019-4635-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,28]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4635"],"URL":"https:\/\/doi.org\/10.1186\/s12913-019-4635-7","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,28]]},"assertion":[{"value":"20 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AR: Honorariums from Gilead and Abbvie; Research Grants from Abbvie, Gilead, Bristol Myers Squibb and Roche.ER: No competing interests to declare.EJA: no competing interests to declare.KA: no competing interests to declare.LT: no competing interests to declare.JFD: Research Grants, and Honorariums from Abbvie, Bristol Myers Squibb, Gilead, Janssen, Merck Sharp & Dohme and Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"765"}}